Open an account

Eli Lilly and

LLY · NYSE

$1,283.66+$43.32 (+3.49%)TodayMarket closed ·
Prev close $1,240.34

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.

Employees
50,000
Headquarters
Indianapolis, Indiana
Listed
Jul 9, 1970
Sector
Health Care
Industry
Pharmaceuticals
Website
lilly.com

LLY key statistics

Market cap
1.17T
Price-earnings ratio
41.62
Dividend yield
0.49%
Average volume
2.30M
Volume
2.14M
Open price
$1,263.50
High today
$1,311.75
Low today
$1,260.17
52 Week high
$1,292.65
52 Week low
$783.85

Eli Lilly and (LLY) at a glance

Eli Lilly and (LLY) last traded at $1,283.66, with a market cap of 1.17T, a price-to-earnings ratio of 41.62 and a dividend yield of 0.49%.

Today the stock has traded between $1,260.17 and $1,311.75. The current price is 1.9% above the day's low and 2.1% below its high.

Volume so far is 2.14M shares, in line with the average of 2.30M shares a day.

Over the past year Eli Lilly and has ranged from $783.85 to $1,292.65, and now sits 98% of the way up that range.

Eli Lilly and met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $8.38 per share against an estimate of $6.07.

The average analyst price target is $1,332.94, 3.8% above the current price, from 22 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

95%of 22 analyst ratings say Buy
  • Buy95.5%
  • Hold0.0%
  • Sell4.5%
Price target · 33 analystsAvg $1,332.94
Low
$900.13
Now
$1,283.66
High
$1,680.00

LLY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 18.5% on average.

  1. Q3 FY24: reported $1.18 per share against an estimate of $1.48
  2. Q4 FY24: reported $5.32 per share against an estimate of $5.00
  3. Q1 FY25: reported $3.34 per share against an estimate of $3.05
  4. Q2 FY25: reported $6.31 per share against an estimate of $5.51
  5. Q3 FY25: reported $7.02 per share against an estimate of $5.75
  6. Q4 FY25: reported $7.54 per share against an estimate of $6.74
  7. Q1 FY26: reported $8.55 per share against an estimate of $6.73
  8. Q2 FY26: reported $8.38 per share against an estimate of $6.07

LLY news

  • Vandana Singh

    Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts

  • Press releasePRNewswire

    Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

  • Press releasePRNewswire

    Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

  • Mohd Haider

    JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms

  • Vandana Singh

    Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes

  • Vandana Singh

    Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients

  • Press releasePRNewswire

    Lilly confirms date and conference call for third-quarter 2026 financial results announcement

  • Press releasePRNewswire

    New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year

Similar companies

Companies in the same industry as Eli Lilly and

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.